SEATTLE GENETICS INC's ticker is SGENXXXX and the CUSIP is 812578102. A total of 297 filers reported holding SEATTLE GENETICS INC in Q2 2018. The put-call ratio across all filers is 1.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $46,212,000 | +53.0% | 271,962 | +3.9% | 0.05% | +24.3% |
| Q1 2020 | $30,208,000 | +0.4% | 261,812 | -0.5% | 0.04% | +37.0% |
| Q4 2019 | $30,076,000 | +76.8% | 263,222 | +32.2% | 0.03% | +58.8% |
| Q3 2019 | $17,008,000 | +59.2% | 199,160 | +29.0% | 0.02% | +30.8% |
| Q2 2019 | $10,683,000 | -17.6% | 154,360 | -12.8% | 0.01% | -18.8% |
| Q1 2019 | $12,969,000 | +45.1% | 177,079 | +12.3% | 0.02% | +23.1% |
| Q4 2018 | $8,935,000 | -32.7% | 157,692 | -8.4% | 0.01% | -23.5% |
| Q3 2018 | $13,272,000 | +16.8% | 172,092 | +0.6% | 0.02% | +6.2% |
| Q2 2018 | $11,359,000 | +5.7% | 171,100 | -16.7% | 0.02% | +6.7% |
| Q1 2018 | $10,745,000 | -6.6% | 205,300 | -4.6% | 0.02% | -6.2% |
| Q4 2017 | $11,508,000 | +1.2% | 215,100 | +2.9% | 0.02% | -5.9% |
| Q3 2017 | $11,372,000 | -3.9% | 209,000 | -8.6% | 0.02% | -10.5% |
| Q2 2017 | $11,828,000 | -16.3% | 228,600 | +1.6% | 0.02% | -17.4% |
| Q1 2017 | $14,137,000 | +17.0% | 224,900 | -1.7% | 0.02% | +15.0% |
| Q4 2016 | $12,079,000 | +1.1% | 228,900 | +3.5% | 0.02% | 0.0% |
| Q3 2016 | $11,947,000 | +25.1% | 221,200 | -6.4% | 0.02% | +33.3% |
| Q2 2016 | $9,549,000 | +11.7% | 236,300 | -3.0% | 0.02% | +7.1% |
| Q1 2016 | $8,551,000 | -35.3% | 243,700 | -17.3% | 0.01% | -33.3% |
| Q4 2015 | $13,226,000 | +32.7% | 294,700 | +14.0% | 0.02% | +23.5% |
| Q3 2015 | $9,964,000 | -11.8% | 258,400 | +10.7% | 0.02% | 0.0% |
| Q2 2015 | $11,297,000 | +45.8% | 233,400 | 0.0% | 0.02% | +54.5% |
| Q1 2015 | $7,749,000 | 0.0% | 233,400 | 0.0% | 0.01% | 0.0% |
| Q4 2014 | $7,749,000 | -10.7% | 233,400 | 0.0% | 0.01% | -8.3% |
| Q3 2014 | $8,678,000 | -2.8% | 233,400 | 0.0% | 0.01% | 0.0% |
| Q2 2014 | $8,928,000 | -8.5% | 233,400 | -1.7% | 0.01% | -14.3% |
| Q1 2014 | $9,758,000 | +11.8% | 237,500 | +9.7% | 0.01% | +7.7% |
| Q4 2013 | $8,729,000 | -8.1% | 216,500 | -0.0% | 0.01% | -27.8% |
| Q3 2013 | $9,494,000 | +40.8% | 216,602 | +1.0% | 0.02% | +28.6% |
| Q2 2013 | $6,744,000 | – | 214,357 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 51,049,760 | $3,738,884,000 | 23.93% |
| Lagoda Investment Management, L.P. | 76,873 | $5,630,000 | 7.16% |
| Matrix Capital Management Company, LP | 3,141,852 | $230,109,000 | 6.14% |
| DOMINI IMPACT INVESTMENTS LLC | 3,120 | $229,000 | 3.51% |
| Opus Point Partners Management, LLC | 17,832 | $1,306,000 | 1.77% |
| Capital International Sarl | 188,200 | $13,784,000 | 1.72% |
| EMORY UNIVERSITY | 33,368 | $2,444,000 | 1.72% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 60,900 | $4,460,000 | 1.65% |
| CAPITAL GUARDIAN TRUST CO | 1,358,254 | $99,415,000 | 1.32% |
| Rhenman & Partners Asset Management AB | 150,598 | $11,030,000 | 1.29% |